This review mainly focuses on the dosimetry methodology which includes consideration of the number and time points of scans, imaging methodology, methods for integrating time-activity curves and calculating absorbed doses. (177)Lu-labelled compounds show many advantages for dosimetry assessments due to attractive physical properties which comprise low abundance of photons for sufficient post-therapy imaging, a clearly separated gamma peak at 208 keV, and a low range of beta particles. The most up-to-date results of absorbed dose calculations for the kidneys, bone marrow, and tumors are provided. The absorbed doses reported for radiopeptide therapies using (177)Lu labelled compounds taken from clinical studies show a high variability, presumably because of the different applied methodologies.